Dr. Reddy’s (NYSE: RDY) Global IPDO head Sushrut Kulkarni resigns

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited has filed a Form 6-K to report that Mr. Sushrut Kulkarni, Global Head of IPDO and Senior Management Personnel, has resigned. He will cease employment and senior management responsibilities effective from the close of business on May 8, 2026, as he plans to explore opportunities outside the company.

The company states that the disclosure is made under Regulation 30 of the SEBI Listing Regulations, with required details provided in an annexure. In his resignation letter, Mr. Kulkarni undertakes to support the company during his notice period and ensure a smooth handover of responsibilities.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

February, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                        Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                        No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated February 09,2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: February 09,2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

	Dr. Reddy's Laboratories Ltd.
	8-2-337, Road No. 3, Banjara Hills
	Hyderabad – 500 034, Telangana, India
	CIN: L85195TG1984PLC004507
	Tel:  + 91 40 4900 2900
	Fax:  + 91 40 4900 2999
	Email: mail@drreddys.com
	Web: www.drreddys.com

February 9, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Change in Senior Managerial Personnel

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that Mr. Sushrut Kulkarni has resigned from the position of Global Head of IPDO and Senior Management Personnel of the Company. He will cease to be in employment and as part of Senior Management Personnel of the Company, effective from the close of business hours on May 8, 2026. The resignation letter as received from Mr. Sushrut Kulkarni is annexed herewith.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in Annexure enclosed herewith.

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR

Encl: as above

Annexure

Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Mr. Sushrut Kulkarni has resigned from the position of Global Head of IPDO and Senior Management Personnel of the Company to explore opportunities outside the Company.
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	May 8, 2026
3	Brief profile (in case of appointment)	Not applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

9^th February, 2026

To,

Mr. Erez Israeli

Dr. Reddy’s Laboratories Limited

8-2-337, Road No-3, Banjara Hills,

Hyderbabad-Telangana-500034

Dear Erez,

Sub: Resignation

I am writing to formally resign from my position as Global Head of IPDO and Senior Management Personnel of Dr. Reddy’s Laboratories Limited, effective May 8, 2026, to explore opportunities outside the organisation.

I confirm that I will continue to support the Company during the notice period and ensure a smooth handover of responsibilities to facilitate the transition of my role. I would like to express my sincere appreciation for the opportunity to be part of the organization and wish the Company continued success in future.

Thanking you and regards,

Sushrut Kulkarni

FAQ

What executive change did Dr. Reddy’s Laboratories (RDY) disclose in this Form 6-K?

Dr. Reddy’s Laboratories disclosed that Mr. Sushrut Kulkarni has resigned as Global Head of IPDO and Senior Management Personnel. The company informed stock exchanges via an intimation dated February 9, 2026, under SEBI Regulation 30 with supporting annexures.

When will Sushrut Kulkarni’s resignation at Dr. Reddy’s (RDY) become effective?

His resignation becomes effective at the close of business hours on May 8, 2026. Until that date, he remains employed and is expected to support the company during the notice period and help ensure a smooth transition of his responsibilities.

What reason did Sushrut Kulkarni give for resigning from Dr. Reddy’s Laboratories (RDY)?

He resigned from his role as Global Head of IPDO and Senior Management Personnel to explore opportunities outside the company. This reason is explicitly stated in the annexure prepared under SEBI Regulation 30 and reiterated in his formal resignation letter.

Under which regulatory framework was the resignation at Dr. Reddy’s (RDY) reported?

The resignation was reported pursuant to Regulation 30 of the SEBI Listing Regulations, 2015. The company also referenced SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, providing the prescribed details of the change in a structured annexure.

What role did Sushrut Kulkarni hold at Dr. Reddy’s Laboratories (RDY) before resigning?

He served as the Global Head of IPDO and was part of the company’s Senior Management Personnel. Both the stock exchange intimation and his resignation letter describe these positions as the roles from which he is stepping down effective May 8, 2026.

Did Dr. Reddy’s (RDY) disclose any relationships or profile details for Sushrut Kulkarni in this filing?

The annexure notes that brief profile and relationship disclosures are not applicable, as this is a resignation rather than an appointment of a director. It only specifies his reason for leaving and the effective cessation date of May 8, 2026.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 38.6 KB